Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/0284186X.2011.562919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.
Curr Oncol Rep
January 2025
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg- Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.
Purpose Of Review: Neuroendocrine tumours (NET) are rare entities arising from hormone producing cells in the gastroentero-pancreatic (GEP) tract. Surgery is the most common treatment of GEP-NETs.
Recent Findings: Improvements in surgical techniques allow for more locally advanced and metastasised GEP-NETs to be resected.
Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy.
Front Oncol
January 2025
Department of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United States.
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy.
View Article and Find Full Text PDFA phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Factors associated with grade progression in pancreatic neuroendocrine tumors.
Endocr Relat Cancer
January 2025
E Bergsland, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States.
Grade progression of well differentiated pancreatic neuroendocrine tumors (panNETs) can occur over time, with G1/2 to G3 the most clinically relevant form. Here we conducted a retrospective cohort study of 66 patients with initially G1/2 panNET (median initial Ki67, 4.6%).
View Article and Find Full Text PDF[Neuroendocrine carcinoma of the extrahepatic bile duct:a case report].
Nihon Shokakibyo Gakkai Zasshi
January 2025
Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine.
A 78-year-old male patient came to our hospital with a chief complaint of fever. Computed tomography revealed an indistinct tumor in the pancreatic head, along with dilatation of the bile duct and main pancreatic duct. An endoscopic transpapillary biopsy demonstrated adenocarcinoma in the glandular epithelium and a dense formation of quasi-round cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!